Search Results

Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase modulators as new therapeutics for areas of high unmet medical need, announced an agreement with Nanna Therapeutics.

Ubiquigent Limited announced an agreement with Debiopharm, a biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases.

Today, Ubiquigent Limited (Ubiquigent) celebrates the 10th anniversary of its DUBprofiler™ compound profiling platform, together with KSQ Therapeutics joining its expanding customer base.

Ubiquigent Limited today announces the extension and expansion of its long-term collaboration with Bristol Myers Squibb.

Ubiquigent Limited (Ubiquigent) announced today that it has entered into a license agreement with Medivir AB (Nasdaq Stockholm: MVIR) for Medivir’s preclinical USP7 research program.

Medivir AB (Nasdaq Stockholm: MVIR) announced today that it had entered into a license agreement with Ubiquigent Limited (Ubiquigent) for Medivir’s preclinical USP7 research program

Ubiquigent Limited (Ubiquigent) today announced the continuation of a collaboration with Bristol Myers Squibb. The collaboration, originally between Ubiquigent and Celgene, will allow Bristol Myers Squibb to capitalise on the strength and breadth of Ubiquigent’s deubiquitylase (DUB) enzyme inhibitor drug discovery platform and expertise. The central role of ubiquitylation in diverse cellular processes, including pr

Ubiquigent Limited (Ubiquigent) and the Mottram Laboratory at the University of York today announced a collaboration to investigate the inhibition of deubiquitylase (DUB) enzymes expressed by the protozoan Leishmania mexicana for the treatment of leishmaniasis

Ubiquigent Limited and LEO Pharma A/S announced that they have entered into an option agreement granting LEO Pharma access to two novel compounds.

Ubiquigent Limited and LEO Pharma A/S announced that they have entered into an option agreement granting LEO Pharma access to two novel compounds.